Research Analysts Set Expectations for ARCT FY2025 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Arcturus Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the biotechnology company will post earnings of ($3.21) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.31) per share.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.44. The business had revenue of $41.67 million for the quarter, compared to analysts’ expectations of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. During the same quarter last year, the firm earned ($0.61) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a report on Monday, January 13th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $66.75.

Arcturus Therapeutics Stock Down 0.3 %

Shares of NASDAQ:ARCT opened at $16.69 on Thursday. The stock has a market cap of $452.13 million, a price-to-earnings ratio of -7.53 and a beta of 2.63. The business’s 50 day moving average is $17.32 and its 200 day moving average is $19.76. Arcturus Therapeutics has a 12-month low of $14.30 and a 12-month high of $45.00.

Institutional Investors Weigh In On Arcturus Therapeutics

Several large investors have recently made changes to their positions in the business. Sumitomo Mitsui Trust Group Inc. increased its holdings in Arcturus Therapeutics by 45.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock worth $52,819,000 after buying an additional 712,650 shares during the last quarter. ARK Investment Management LLC increased its stake in shares of Arcturus Therapeutics by 6.9% during the 3rd quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company’s stock worth $48,765,000 after purchasing an additional 136,074 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Arcturus Therapeutics by 250.1% in the 2nd quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock worth $13,515,000 after purchasing an additional 396,505 shares during the period. Geode Capital Management LLC lifted its stake in Arcturus Therapeutics by 1.1% in the third quarter. Geode Capital Management LLC now owns 551,798 shares of the biotechnology company’s stock valued at $12,810,000 after purchasing an additional 5,789 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Arcturus Therapeutics by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company’s stock valued at $4,587,000 after purchasing an additional 3,224 shares during the period. 94.54% of the stock is owned by hedge funds and other institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.